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Abstract
Background: Innate immune cells such as macrophages are abundantly present within malignant ascites, where
they share the microenvironment with ovarian cancer stem cells (CSC).
Methods: To mimic this malignant ascites microenvironment, we created a hanging-drop hetero-spheroid model
to bring CSCs and macrophages in close association. Within these hetero-spheroids, CD68+ macrophages (derived
from U937 or peripheral blood monocytes) make up ~ 20% of the population, while the rest are ovarian cancer
cells and ovarian cancer stem cells (derived from the high grade serous ovarian cancer cell line, OVCAR3).
Results: Our results indicate that CSCs drive the upregulation of M2 macrophage marker CD206 within hetero-
spheroids, compared to bulk ovarian cancer cells, implying an inherently more immuno-suppressive program.
Moreover, an increased maintenance of elevated aldehyde dehydrogenase (ALDH) activity is noted within hetero-
spheroids that include pre-polarized CD206+ M2 macrophages, implying a reciprocal interaction that drives pro-
tumoral activation as well as CSC self-renewal. Consistent with enriched CSCs, we also observe increased levels of pro-
tumoral IL-10 and IL-6 cytokines in the CSC/M2-macrophage hetero-spheroids. CSC/M2-macrophage hetero-spheroids
are also less sensitive to the chemotherapeutic agent carboplatin and are subsequently more invasive in transwell
assays. Using inhibitors of WNT secretion in both CSCs and macrophages, we found that CSC-derived WNT ligands
drove CD206+ M2 macrophage activation, and that, conversely, macrophage-derived WNT ligands enriched ALDH+
cells within the CSC compartment of hetero-spheroids. Upon examination of specific WNT ligand expression within the
monocyte-derived macrophage system, we observed a significant elevation in gene expression for WNT5B. In CSCs co-
cultured with macrophages within hetero-spheroids, increases in several WNT ligands were observed, and this increase
was significantly inhibited when WNT5B was knocked down in macrophages.
Conclusions: Our data implies that macrophage- initiated WNT signaling could play a significant role in the
maintenance of stemness, and the resulting phenotypes of chemoresistance and invasiveness. Our results indicate
paracrine WNT activation during CSC/M2 macrophages interaction constitutes a positive feedback loop that likely
contributes to the more aggressive phenotype, which makes the WNT pathway a potential target to reduce the CSC
and M2 macrophage compartments in the tumor microenvironment.
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Introduction
Late stage epithelial ovarian cancer presents frequently
with peritoneal carcinomatosis, and is associated with the
formation of malignant ascites. Exfoliated ovarian cancer
cells exist as spheroids within the ascites microenviron-
ment, and there is also an enrichment of ovarian cancer
stem cells (CSCs) within the peritoneal fluid [1–3]. Within
the malignant ascites, CSCs interact with a variety of host
cells including different immune subsets in the presence
of a complex cytokine/chemokine network, ultimately
leading to trans-coelomic metastasis [4–6]. Also found in
abundance within the peritoneal ascites fluid are macro-
phages, which are generally believed to be polarized and
educated by tumor-derived factors into an M2-resembling
pro-tumoral phenotype. In fact, ovarian cancer cells inter-
act with macrophages in anchorage independent condi-
tions and grow as spheroids within the malignant ascites,
which can result in tumor metastasis even during the early
stage of peritoneal dissemination [7].
In the ovarian cancer microenvironment, macrophages
are activated into a tumor-associated macrophage (M2-like,
“M2”, alternatively activated) phenotype primarily through
education by tumor-derived cytokines, chemokines and
other tumor cell-derived factors [8, 9]. Tumor-associated
macrophages within malignant ascites have a bipolar ex-
pression spectrum, ranging from M1-like to M2-like phe-
notypes. However, M2-like macrophages are the primary
pro-tumoral phenotype in the peritoneal cavity. In fact, a
high ratio of M1/M2 macrophages is associated with an im-
proved prognosis in ovarian cancer, whereas lower M1/M2
ratio is indicative of a poor prognosis [10–12].
Little is known about the specific role of cancer stem
cells in macrophage polarization and activation. Even less
is known about the reciprocal interactions between CSCs
and macrophages. Given the enriched presence of macro-
phages and CSCs within the malignant ascites, their inter-
action may be critical for regulating the progression and
drug response of ovarian cancer. Therefore, in this study,
we used a previously established in vitro hanging drop
spheroid model [13–15] to dissect the reciprocal interac-
tions between the CSCs in tumor spheroids and macro-
phages. The hanging drop spheroid model allows the
formation of stable spheroids in a non-adherent 3D in
vitro environment, similar to the aggregation of ovarian
cancer cells floating within the malignant ascites in
anchorage-independent conditions. We previously dem-
onstrated that the hanging drop spheroid model maintains
CSCs derived from primary patient samples with high fi-
delity, and preserves responses to chemotherapeutic
agents similar to mouse xenograft models [13].
The importance and abundance of WNT-signaling have
been demonstrated in ovarian development, tumorigenesis
and stem cell maintenance [16, 17]. In the tumor immune
microenvironment, activated WNT/β-catenin signaling
can suppress the recruitment of dendritic cells, thereby
limiting T-cell priming, and intra-tumoral T-cell accumu-
lation [18]. WNT signaling is also heavily involved in the
activation of macrophages [19, 20]. Importantly, paracrine
WNT signaling loops between M2-like macrophages and
tumor cells contribute to tumorigenesis and invasiveness
[21, 22].
We hypothesized that any trophic interactions be-
tween CSCs and macrophages may involve a WNT-
dependent pathway. Therefore, using the hanging drop
spheroid model, we sought to understand pro-tumoral
macrophage activation in response to CSCs, and changes
in the CSC compartment itself in response to activated
macrophages. We evaluated the WNT pathway in CSC-
macrophage interactions, and whether that corre-
sponded to functional changes in chemoresistance or in-
vasion of CSC spheroids. Insight into WNT involvement
in CSC-macrophage interactions could provide new tar-
getable avenues to reduce CSC-burden in ovarian cancer,
thereby limiting metastatic and recurrent disease.
Materials and methods
Materials
Cell lines were purchased from ATCC (Manassas, VA).
Peripheral blood mononuclear cells (PBMCs) were puri-
fied from buffy coats from healthy donors through Ficoll-
Paque gradient centrifugation. Cytokines were purchased
from Peprotech Inc., and all other tissue culture supple-
ments from Life Technologies, and chemicals from Sigma
Aldrich (St. Louis, MO) unless otherwise specified. Com-
pounds Ruxolitinib and sc144 were a generous gift from
the laboratory of Dr. Karen McLean. Viral vectors were
purchased from Sigma Aldrich and packaged at the Uni-
versity of Michigan Viral Vector core.
Derivation and polarization of macrophages from U937
cell line, and PBMCs
U937 cells were cultured in suspension in RPMI supple-
mented with 10% heat-inactivated fetal calf serum (At-
lanta Biologics) and 1x antibiotics/antimycotics. Cells
were harvested, and suspended at 2500cells/ml and
treated with 5 ng/ml phorbol myristate acetate (PMA).
20 μl of this suspension was plated onto each well of a
hanging drop array plate, to allow monocytes to differ-
entiate into macrophages in suspension culture. For
PBMCs, cells were plated onto tissue culture dishes, and
the non-adherent cell fraction was discarded following
24 h of attachment. PBMCs were then detached from
the plate, and plated onto hanging drop arrays at 500
cells/drop. At the end of 24 h, each well was left un-
treated to derive M0 resting macrophages, or treated
with 20 ng/ml recombinant human M-CSF and 20 ng/ml
IL-4 to derive activated M2-like macrophages for the
next 48 h. For brevity, figure captions refer to IL-4/
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MCSF activated macrophages as M2, to indicate the
M2-like, alternatively activated phenotype. Macrophages
were harvested from hanging drops and assessed for dif-
ferentiation and polarization using flow analysis, de-
scribed below. Harvested macrophage aggregates were
also subjected to subsequent qPCR analysis, or used to
manufacture hetero-spheroids.
Isolation of ovarian CSCs from ovarian cancer cell lines
Ovarian CSCs were isolated from the serous ovarian can-
cer cell lines OVCAR3 (used under passage 35) as de-
scribed previously [13]. Briefly, cells were harvested and
incubated with ALDEFLUOR reagent, and CD133 anti-
body, and sorted using flow cytometry for cells positive
for elevated ALDH and CD133 positivity. Appropriate
DEAB and isotype controls were used for both assays, to
determine gate settings as described previously. CSCs
were freshly sorted and used to make hetero-spheroids <
24 h after flow sorting.
Formation of mono- and hetero-spheroids from CSCs and
macrophages
Spheroids were generated on a hanging drop array plate
from CSCs and macrophages adapting protocols described
previously [13–15]. For mono-spheroids, 100 CSCs or the
unsorted bulk of OVCAR3 cells were seeded per hanging
drop and allowed to form spheroids. Macrophages were
harvested from hanging drops following the differentiation
protocol described in Section 2.2. Macrophages and CSCs
were combined and plated onto hanging drop arrays such
that each drop contained 100 CSCs and 100 M0/M2 mac-
rophages. Mono-spheroids contained 100 CSCs or bulk un-
sorted OVCAR3 cells. Following 4–5 days in hanging drop
array culture, spheroid formation was tracked using live cell
microscopy and routinely fed to maintain a ~ 20 μl drop
volume. Spheroids were used for subsequent flow analysis,
qPCR or lysed to obtain protein for immunoblots. In some
instances, hetero-spheroids were manufactured from CSCs
stably expressing GFP, and fluorescent activated cell sorting
was utilized to separate the GFP+ CSC compartment from
hetero-spheroids for further analysis.
Flow cytometry analysis
Flow cytometry analysis was performed following proto-
cols established in our lab previously [13]. CD68-APC
(Miltenyi Biotech, Germany) antibody was used, with its
associated APC-isotype control, to identify CD68+ mac-
rophages, in differentiated U937 or PBMC monocytes,
and hetero-spheroids. For CD68 flow analysis, samples
were fixed in methanol at − 20 °C, for 1 h, followed by a
PBS wash to remove methanol, re-suspension in FACS
Buffer (PBS + 2% FBS) before antibody incubation.
Two kinds of flow cytometry based experiments were
carried out to characterize hetero-spheroids: i) macrophage
polarization was assessed by CD68+ and CD206+ using flow
cytometry; ii) Stemness was assessed by ALDEFLUOR
assay for observation of elevated ALDH activity using flow
cytometry, using protocols established previously [13].
Briefly, hetero-spheroids were harvested in FACS buffer,
and triturated to single-cell suspensions. Appropriate
isotype controls were used for conjugated antibodies, to set
gates to observe CD68 and CD206. For ALDH, a molar ex-
cess of the DEAB inhibitor was used to determine positive
gates per the manufacturer’s protocol, to identify elevated
ALDH activity. ALDH activity was assessed following 48-h
treatment with the JAK1/2 inhibitor, Ruxolitinib, or the
GP130 inhibitor, sc144, or the human anti IL-6 antibody,
Tocilizumab (Actemra, Genentech). Flow cytometry was
performed on the Attune acoustic focusing flow cytometer
(Applied Biosystems). Flow sorting was performed on the
Astrios (Beckman Coulter).
Gene expression via qPCR
RNA was extracted from harvested macrophages or hetero-
spheroids using the RNeasy extraction kit (Qiagen). Ex-
tracted RNA was assessed for concentration and purity
using a Nanodrop 2000 (Thermo Fisher Scientific) spectro-
photometer. RNA was transcribed to cDNA using the
High-fidelity cDNA Transcription kit (Life Technologies),
and qPCR was carried out in the 96-well format using the
7900HT platform (Applied Biosystems). For macrophage
polarization, CD163 and CD206 were assessed. IL-10 was
additionally assessed in hetero-spheroids. Lastly, WNT li-
gands were also assessed in hetero-spheroids. Gene expres-
sion differences were quantified using the 2ΔΔCT method,
using GAPDH as the housekeeping control, and reported
as fold change compared to a control sample. For macro-
phages, controls were undifferentiated monocytes. For
hetero-spheroids, control samples were bulk OVCAR3
spheroids. qPCR experiments were run in triplicates, with
2–3 independent samples. A list of primers used in the
qPCR experiments is provided in Additional file 1: Table
S1.
Quantification of cytokines using ELISA
For ELISA assays, media was harvested from 50 spher-
oids (macrophages, OVCAR3, CSC, CSC/M2 or CSC/
sh-WNT5B M2). ELISA assays were performed on the
Duoset ELISA system (R&D Biosystems, Minneapolis
MN) following the manufacturer’s protocol, modified to
include an overnight sample incubation. Cytokines ana-
lyzed included IL-10 and IL-6. Standard curves were
generated for each cytokine, and analyte concentration
was assessed using a four parametric ELISA curve, to
determine the amount of IL-10 or IL-6 released. ELISA
assays and data analysis were performed at the Immuno-
logical Monitoring Core at the Rogel Cancer Center,
University of Michigan.
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Assessment of chemoresistance in hetero-spheroids
For chemoresistance, hetero-spheroids were treated with
carboplatin, to a final concentration of 300 μM, within
20 μl drops, for 48 h. At the end of 48 h, the MTS re-
agent (Abcam) was added to drops at a 1/10 dilution,
and allowed to incubate at 37 °C for 2.5 h. At the end of
the incubation period, absorbance was read on the
hetero-spheroids at 590 nm, according to manufacturer’s
protocols. Untreated hetero-spheroids were used as con-
trols, to normalize the absorbance to identify the effect
of drug treatment on cellular viability. Results were
quantified as normalized cell viability, based on un-
treated controls. Experiments were repeated with 3–5
biological replicates for statistical analysis.
Assessment of migration of hetero-spheroids
In order to quantify invasiveness of hetero-spheroids, 8 μm
transwell inserts were placed in each well of a 24 well
plate. 10 CSC mono-spheroids or CSC/M2, CSC/scramble
M2, CSC/sh-WNT5B M2 hetero-spheroids were harvested
at Day 5 from hanging drop arrays, and placed on the top
chamber of a transwell insert. The bottom chamber was
filled with 400 μl of fresh medium, so only the bottom of
the transwell insert was immersed in medium. Following 3
days, the transwell insert was removed, and several images
of the bottom of the 24 well were obtained using phase
contrast microscopy. Image J was used to quantify the
number of cells in a field of view. At least four random
non-overlapping fields of view were counted from each ex-
periment, to find the number of cells that migrated through
the transwell insert to the bottom of the well.
Immuno-blotting for β-catenin
Hetero-spheroids were harvested and lysed in 200 μl of
Radio-immunoprecipitation assay (RIPA) Buffer, soni-
cated for 30s on ice with a probe sonicator. Extracted
concentration was measured using the BCA Assay Re-
agent (Pierce) following manufacturer’s protocol for a
96-well format. Subsequently, 50 μg of protein from each
sample was loaded onto 4–20% gradient polyacrylamide
gels (Biorad), and separated electrophoretically, trans-
ferred to a PVDF membrane. Transferred membranes
were blocked with 5% non-fat milk, and probed with β-
catenin (R&D Biosystems) overnight at 4 °C, washed
with TBST buffer, and probed with an appropriate HRP-
conjugated secondary antibody. β-Actin was used as a
loading control to determine changes in β-catenin ex-
pression among samples. ECL reagent (Pierce Protein
Biology) was used to visualize bands in a Biorad Chemi-
Doc Touch instrument. Digital images acquired were
processed through NIH Image J, and band analysis tools
were used for densitometry. Band densities were normal-
ized against the loading control β-Actin, to determine
changes.
Knock-down of WNT5B in macrophages
Mission shRNA plasmids were obtained transformed into
E. coli from Sigma Aldrich, targeted to WNT5B
(TRCN0000123194). Transformed E. coli were grown in LB
medium. Plasmid DNA was isolated using the Promega
DNA isolation kit following manufacturer’s protocols, and
2.5 μg of DNA was transfected along with packaging pro-
viral plasmids into HEK293-T cells. Lentivirus particles
were isolated at 1X concentration by the University of
Michigan Viral Vector Core. 1 × 105 cells were transduced
with 3 μg/ml polybrene and 0.5X lentivirus for 30min at
800 g, at 32 °C in a centrifuge. Resulting pellets were re-
suspended in fully supplemented growth medium for 72 h.
At the end of 72 h, cells were harvested for qPCR analysis,
or for macrophage differentiation and further experimenta-
tion. Lentiviruses were packaged to express shRNA target-
ing WNT5B (sh-WNT5B), or scrambled shRNA (sh-
scramble). Sh-WNT5B or sh-scramble treated U937 mono-
cytes were differentiated and activated into macrophages
following protocols described in section 2.2.
Assessment of tumorigenicity in vivo of hetero-spheroids
CSC mono-spheroids and CSC/M2 and CSC/sh-WNT5B
M2 hetero-spheroids were generated following protocols
outlined in Section 2.4. CSCs were GFP tagged in these
spheroids, and after five days of hetero-spheroid culture,
CSCs were isolated using the GFP label prior to sub-
cutaneous injection into NSG mice. Each tumor received
CSCs from 10 spheroids. Tumor initiation and monitoring
protocols were performed as described previously [13].
When palpable tumors were observed, tocilizumab (10
mg/kg, intra peritoneally) treatment began 3 times/week.
Tumors were allowed to grow till the end-point was
reached for maximum tumor burden, and mice were eu-
thanized. Tumors were dissected, and routine paraffin
histology and H&E staining was performed, to understand
any changes in histology. RNA was isolated from tumors
following protocols outlined in Section 2.6, and subject to
qPCR for ALDH1A1, and several other Wnt ligands.
Data analysis and statistics
Experiments were carried out using 3–5 biological repli-
cates for U937-derived macrophages, and OVCAR3-
derived CSCs. GraphPad Prism 5.0 (www.graphpad.com)
was utilized to perform all statistical analysis. When ap-
propriate, one-way ANOVAs were used to test signifi-
cant differences, and if differences were observed,
indicated with symbols and a significance level.
Results
Monocyte-derived macrophages can be differentiated
and activated in 3D hanging drop cultures
The monocytic cell line, U937, or healthy-donor derived
PBMCs were placed in hanging drop cultures. In the
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presence of PMA, U937 and PBMC monocytes differ-
entiated into macrophages, and over the course of 72
h, they were organized as a compacted mass of cells
within hanging drop cultures (Fig. 1a). Monocytes
with no PMA stimulation, in contrast, were extremely
loosely aggregated and did not form compact spher-
oids. Differentiated macrophages were indicated as
M0 macrophages, implying differentiation with no
cytokine stimulation. 74.6 ± 8.2% of U937 monocytes
differentiated into M0 macrophages expressed the pan
macrophage marker CD68. Similarly, PBMCs also dif-
ferentiated into macrophages upon PMA stimulation,
with 84.3 ± 8.5% CD68 expression (Fig. 1b). Mono-
cytes were also differentiated and polarized into an al-
ternatively activated phenotype (M2; Fig. 1a). These
macrophages were derived with PMA stimulation in
the presence of IL-4 and M-CSF. Alternately activated
M2-like macrophages, either from U937 or PBMCs
had an associated increase in gene expression of
CD163 and CD206 (Fig. 1c). Immuno-suppressive
cytokine IL-10 and tumor-promoting cytokine IL-6
were elevated in M2-polarized macrophages from
both U937 and PBMC compared to M0 macrophages,
or undifferentiated monocytes, indicating a shift in
phenotype between M0 and M2-like macrophages de-
rived using this culture system (Fig. 1d). In summary,
macrophages could be derived from U937 or PBMC
monocytes using the 3D hanging drop culture system,
and could be further activated into a M2-phenotype.
3D differentiation and activation was similar in terms
of gene expression to conventionally activated macro-
phages in 2D culture systems, including elevated argi-
nase enzyme activity (Additional file 1: Figure S1).
Hetero-spheroids can be derived from ovarian cancer
stem cells and macrophages using hanging drop cultures
Hetero-spheroids combining ovarian CSCs derived
from the OVCAR3 cell line and monocyte-derived mac-
rophages (U937 or PBMC) in a starting ratio of 1:1
were generated using hanging drop arrays. Phase con-
trast images of hetero-spheroids at Day 5 indicate com-
pact spheroid formation with tight defined boundaries
(Fig. 1e). No significant differences in size or prolifera-
tive index were observed between CSC mono-
spheroids, and CSC/M0 or CSC/M2 hetero-spheroids
Additional file 1: Figure S2). Hetero-spheroids retained
between 19.2 ± 1.5%-26.3 ± 1.8% expression of CD68+
macrophages at Day 5 (Fig. 1f ). Gating strategy for flow
analysis is presented in Additional file 1: Figure S3.
CSC/M0 or CSC/M2 hetero-spheroids thereby
maintained robust macrophage populations within the
spheroids, while maintaining compact spheroid archi-
tecture for 5 days.
Ovarian cancer stem cells drive CD206 expression in M0
monocyte-derived macrophages within hetero-spheroids
through IL10 and Wnt-signaling
In order to understand if there are differences in bulk
ovarian cancer cells (OVCAR3), and ovarian cancer
stem cells (ALDH+ CD133+ CSC) in their ability to
drive an immuno-suppressive macrophage phenotype,
we generated hetero-spheroids from OVCAR3/M0
and CSC/M0. OVCAR3 or CSC mono-spheroids dem-
onstrate minimal expression of CD206 (0.9–1%,
Fig. 2a, Additional file 1: Figure S4). When comparing
differences in CD206 expression between OVCAR3/
M0 or CSC/M0 hetero-spheroids, a significant (**p <
0.001, one-way ANOVA) 20% increase in CD206 was
observed with CSC co-culture (Fig. 2a), indicating
that ovarian CSCs drive an immuno-suppressive
phenotype in macrophages compared to bulk ovarian
cancer cells. CSC/M2 hetero-spheroids also expressed
another alternately activated M2 macrophage marker,
CD163 (Additional file 1: Figure S5). We sought to
explore whether there are differences in the immuno-
suppressive cytokine IL-10 between OVCAR3 and
CSC spheroids. We found that IL-10 gene expression
was significantly elevated (2-fold) in CSC mono-
spheroids compared to OVCAR3, which was even
more pronounced in CSC/M0 spheroids compared to
OVCAR3/M0 (Fig. 2b). In hetero-spheroids derived
from M2 macrophages and CSCs, CD206 expression
was maintained through co-culture (Fig. 2c). Higher
secreted IL-10 levels were observed in CSC/M2
hetero-spheroids (Fig. 2d).
We then explored the possibility of a factor other than
IL-10 driving CD206 expression in macrophages. Given
the importance of the WNT signaling cascade in both
Ovarian CSC maintenance as well as macrophage
polarization and activation, we inhibited all WNT secre-
tion from Ovarian CSCs using an inhibitor, IWP-2.
When hetero-spheroids were generated from IWP-2
treated CSCs and M0 or M2 macrophages, CD206 ex-
pression significantly decreased (44–62%) in hetero-
spheroids (*p < 0.05, one-way ANOVA; Fig. 2e), with no
associated change in CD68 expression. Concomitantly,
we found the gene expression of several Wnt ligands ele-
vated close to 2-fold in CSC compared to bulk OVCAR3
spheroids (Fig. 2f ). Furthermore, we found an associated
30% increase in beta-catenin protein expression, indicat-
ing an increased canonical Wnt signaling axis in CSC/
M2 spheroids (Fig. 2g).
In short, in CSC-macrophage interactions within
hetero-spheroids, we found not only elevated levels of
the immuno-suppressive cytokine IL-10, but also of
several WNT ligands. We also noted a dependency of
M2 macrophage activation on CSC-derived WNT
ligands.
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Alternatively activated M2 macrophages increase ovarian
CSC populations within hetero-spheroids through IL-6
signaling, and are more chemoresistant and invasive
We then investigated the maintenance of stemness within
hetero-spheroids, since we hypothesized that alternative
macrophage activation may result in a pro-tumoral reci-
procity within hetero-spheroids. Flow analysis for elevated
ALDH indicated that M2 hetero-spheroids significantly
and robustly (**p < 0.001, one-way ANOVA) increased the
maintenance of ALDH+ populations within hetero-
spheroids, compared to CSC mono-spheroids (Fig. 3a).
Macrophages themselves do not significantly express
elevated ALDH in this assay (Additional file 1: Figure S6).
A ~ 2 fold increase in ALDH+ populations was observed
with co-culture with either U937M2 or PBMC M2 hetero-
spheroids, indicating that M2 activation resulted in im-
proved ovarian CSC maintenance. Concomitant with this
increase in ALDH, we also observed increased secretion of
the IL-6 pro-tumoral cytokine (Fig. 3b). Consequently, in-
hibition of IL-6 signaling with two small molecule inhibi-
tors, Ruxolitinib or SC144 during the formation of CSC/
M2 hetero-spheroids significantly (**p < 0.001, one-way
ANOVA) reduced the enrichment of ALDH+ cells (Fig. 3c).
Our results indicate that the IL-6 signaling axis initiated by
Fig. 1 Hetero-spheroids derived from monocyte-derived macrophages and ovarian cancer stem cells. a Monocytes from the U937 cell line or
peripheral blood monocytes (PBMC) were plated into hanging drop arrays, and differentiated to M0 macrophages with phorbol ester treatment,
or activated with IL-4 and MCSF treatment. Differentiated and activated macrophages formed compact spheroid-like aggregates. b Differentiated
M0 and M2 macrophages all expressed pan macrophage marker, CD68 indicating 75–80% differentiation efficiency from monocytes to
macrophages. CD68 expression was evaluated using flow cytometry analysis, with representative plots. c Polarization was assessed using qPCR
analysis for two M2 genes, CD163 and CD206. Both U937 and PBMC macrophages expressed significantly higher levels of CD163 and CD206
genes, compared to untreated undifferentiated monocytes. d M2 differentiated macrophages secreted higher amounts of the immuno-
suppressive cytokine IL-10, and the pro-tumoral cytokine IL-6. e CSCs were derived from the OVCAR3 cell line based on ALDH+ CD133+
expression. Hetero-spheroids were generated using differentiated U937 or PBMC M0 macrophages and CSCs or activated U937 or PBMC M2
macrophages and CSCs. Representative phase contrast images of hetero-spheroids seen at Day 5 following formation indicate compact
spheroids, similar in size to CSC mono-spheroids generated from the same number of CSCs/spheroid. f Hetero-spheroids retain ~ 20% CD68
expression, indicating that at day 5, CD68+ macrophages constitute 20% of the population of cells. Scale bar = 200 μm
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M2 macrophage co-culture significantly increases mainten-
ance of ALDH+ CSCs within hetero-spheroids.
As a consequence of ALDH+ enrichment, CSC/M2
hetero-spheroids were markedly (**p < 0.001, p < 0.05,
one-way ANOVA) chemoresistant to carboplatin treat-
ment (Fig. 3d). Phase contrast images of drug-treated
spheroids demonstrated the loss of integrity of the tight
spheroid borders in CSC mono-spheroids, whereas the
loss of compactness and integrity was less visually obvious
in CSC/M2 hetero-spheroids (Fig. 3d). Concomitant with
increased drug resistance, CSC/M2 hetero-spheroids were
also significantly (*p < 0.05, one-way ANOVA) more inva-
sive (2–2.6 fold) in transwell assays compared to CSC
mono-spheroids (Fig. 3e).
Our experiments indicated that culturing CSCs within
CSC/M2 hetero-spheroids resulted in increased main-
tenance of ALDH+ CSC populations, which translated to
functional increases in chemoresistance, and invasive-
ness of CSC/M2 hetero-spheroids. Further, blocking in-
creased IL-6 related signaling in CSC/M2 hetero-
spheroids with small molecule inhibitors reduced the
maintenance of CSCs within hetero-spheroids.
Fig. 2 Hetero-spheroids drive CD206 polarization in monocyte-derived macrophages. a Hetero-spheroids were generated from bulk unsorted
OVCAR3 cells and M0 macrophages (OVCAR3/U937M0), and CSC/U937M0. Flow analysis for the macrophage polarization marker CD206
indicated that while OVCAR3 and CSCs by themselves do not express CD206, CSCs drive CD206 expression in previously CD206− M0
macrophages within hetero-spheroids at significantly (**p < 0.001, one-way ANOVA) higher levels than OVCAR3. Representative flow analysis plots
are shown. b IL10 gene expression was evaluated using qPCR in mono- and hetero-spheroids, indicating that CSCs had a 2-fold increased gene
expression of IL10, likely driving CD206 expression in M0 macrophages to higher extents than OVCAR3. c CD206 expression was maintained at
elevated levels (18.5–29.24%) in all CSC hetero-spheroid conditions, indicating that the activated M2 phenotype was maintained in macrophages
within hetero-spheroids. d Levels of secreted IL-10 were mildly elevated in CSC/M2 hetero-spheroids, but were also similar across all CSC/
macrophage hetero-spheroids, indicating the presence of the immuno-suppressive cytokine. e When CSCs were pre-treated with the Wnt
secretion inhibitor, IWP-2, significantly lower (*p < 0.05,one-way ANOVA) CD206 expression was observed in CSC/M2 hetero-spheroids, implying
the importance of CSC-derived Wnt ligands in the maintenance of M2 activation in macrophages. f qPCR analysis revealed that gene expression
of several Wnt ligands were elevated in CSC compared to bulk OVCAR3 spheroids (dotted line = no change); (g) Densitometric measurements of
immunoblots for β-catenin compared to the loading control β-actin indicated that CSC/M2 spheroids had a 26% increase in β-catenin expression,
compared to CSC mono-spheroids, indicating higher Wnt/β-catenin activity in CSC/M2 hetero-spheroids
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Increased WNT signaling in macrophages is responsible
for the pro-tumoral and immuno-suppressive phenotype
observed in M2-hetero-spheroids
We hypothesized that similar to CSCs, M2-like macrophage
activation may also result in increased WNT signaling. We
blocked pan-WNT ligand secretion in M2 macrophages by
treatment with IWP-2 following polarization. CSC/IWP2
M2 hetero-spheroids assumed different aggregation morph-
ology and were less compact (Fig. 4a). Furthermore, ALDH
expression was significantly lower (**p < 0.001, one-way
ANOVA) in CSC/IWP2 M2 hetero-spheroids compared to
CSC/M2, with minimal reduction in CD206 expression
(Fig. 4b), indicating that macrophage-derived WNT signal-
ing may at least be partially responsible for the phenotypes
observed in ovarian CSCs. We investigated the expression
of WNT ligands in macrophages, and found WNT5B over-
expressed ~ 32 fold in M2 macrophages compared to
monocytes using qPCR. We used an shRNA plasmid target-
ing the WNT5B ligand (sh-WNT5B) and a non-targeted
plasmid (sh-Scramble), and used lentiviral methods to si-
lence WNT5B expression in monocytes, with a knockdown
efficiency of 76% (Fig. 4c). Macrophages derived from sh-
WNT5B were termed sh-WNT5B M2. Despite > 75%
knock-down efficiency of WNT5B in monocytes, Alternate
M2-like activation still resulted in an increase in gene ex-
pression of WNT5B. However, we found that monocytes
treated with sh-WNT5B showed a 52% reduction in
WNT5B expression compared to control or scramble M2
Fig. 3 M2-polarized macrophages increase ALDH+ in CSC/M2 hetero-spheroids. a Elevated ALDH activity was assessed using the ALDEFLUOR
flow cytometric analysis assay, with representative flow plots demonstrated. CSC/M2 hetero-spheroids, whether U937 or PBMC, have significantly
(**p < 0.001, one-way ANOVA) elevated ALDH+ expression (1.8–2.4 fold). b Secreted pro-tumoral cytokine IL6 is elevated in hetero-spheroids
compared to CSC mono-spheroids. c We suppressed signaling through the IL6/STAT3 axis using two inhibitors Ruxolitinib and sc144 in hetero-
spheroids, and observed that this suppression also significantly (**p < 0.001, one-way ANOVA) decreased the ALDH+ enrichment within CSC/M2
hetero-spheroids. d Concomitant with the ALDH expression within hetero-spheroids, sensitivity to carboplatin was evaluated using the MTS assay.
Normalized absorbance values indicated that CSC/M2 hetero-spheroids were significantly (*p < 0.05, one-way ANOVA) more resistant to
carboplatin treatment compared to CSC mono-spheroids made with the same number of CSCs. e Representative phase contrast images indicate
the loss of the tight spheroid boundaries in the CSC mono-spheroids in response to carboplatin treatment, indicative of cell death. The extent of
the loss of boundary integrity is much lower in the CSC/M2 hetero-spheroids. Scale bar = 100 μm. f Quantification of the number of migrated
cells in the lower chamber of a transwell system indicated that CSC/M2 hetero-spheroids were significantly (*p < 0.05, one-way ANOVA) more
migratory compared to CSC mono-spheroids
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macrophages (Fig. 4d). WNT5B knockdown did not alter
the CD68+ marker expression (Fig. 4e). Treatment with IL-
4/M-CSF to induce macrophage polarization resulted in in-
creased gene expression for CD163 and CD206, indicating
the development of an alternate M2-like phenotype (Fig.
4f). Therefore, knockdown of WNT5B using sh-WNT5B
did not significantly alter the differentiation of monocytes to
macrophages, or the development of an M2 activated
phenotype. However, a significant loss in WNT5B gene ex-
pression was observed.
WNT5B is involved in M2 macrophage-CSC interactions,
leading to chemoresistance, invasiveness, and increased
stemness
Hetero-spheroids were generated with CSCs and Scram-
ble M2 or sh-WNT5B M2. No significant differences in
CD206 expression was observed in these hetero-
spheroids, indicating that in co-culture, macrophage
knockdown of WNT5B was dispensable for the expres-
sion of CD206 (Fig. 5a). However, macrophage knock-
down of WNT5B resulted in a significant (*p < 0.05,
Fig. 4 Inhibition of macrophage Wnt-secretion reduces ALDH enrichment in hetero-spheroids. a Representative phase contrast image of a hetero-
spheroid generated from CSCs and IWP-2 treated U937M2 macrophages, indicates the formation of aggregated spheroids. Scale bar = 200 μm. b Flow
analysis revealed that hetero-spheroids with IWP-2 treated M2 macrophages had a significantly diminished ALDH+ enrichment (**p < 0.001, one-way
ANOVA) compared to control untreated CSC/M2 hetero-spheroids. However, no change in CD206 expression was observed in hetero-spheroids. c
Transduction efficiency of monocytes with shRNA directed against WNT5B indicated a > 75% efficiency in knockdown of WNT5B gene expression in
the shWnt5b targeted construct, and minimal changes in WNT5B gene expression in the scramble non-targeted lentiviral construct. d We utilized
shWnt5b monocytes to differentiate and polarize M2 macrophages, and found that there was a 52% reduction in WNT5B gene expression in shWnt5b
M2 macrophages, compared to scramble or control untreated M2 macrophages, indicating the knockdown of the Wnt5b gene. e No changes were
observed in CD68 expression in monocytes generated from scramble or shWNT5B treated monocytes, demonstrated by flow analysis and
representative plots. f Similarly, qPCR analysis of M2 gene expression markers CD163 and CD206 indicated increases in both genes, indicative of
activation into the M2 program even in shWnt5b macrophages
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one-way ANOVA) decrease in ALDH+ compartment by
over 5-fold, indicating that macrophage-derived WNT5B
was crucial for the enrichment of CSC characteristics
within hetero-spheroids (Fig. 5b). This reduction in the
ALDH+ enrichment was also associated with an in-
creased sensitivity to carboplatin (Fig. 5c), and a de-
creased invasive potential (Fig. 5d). Upon examination of
cytokine profiles, we observed no significant differences
in IL-10 (Fig. 5e). However, the pro-tumoral CSC-
promoting cytokine IL-6 was completely abrogated in
the CSC/sh-WNT5B M2 hetero-spheroids, indicating
that WNT5B was likely also driving CSC phenotypes
through IL-6 secretion. We explored the possibility of
restoring the CSC enrichment phenotype by the addition
of exogenous IL-6. Upon exogenous addition of IL-6,
levels of ALDH+ cells increased within CSC/sh-WNT5B
M2 hetero-spheroids, indicating that IL-6 is a key ef-
fector downregulated upon WNT5B knockdown, but
may likely not be the only mediating factor in promoting
CSC maintenance via WNT5B (Fig. 5f ). Concomitant
with the loss of IL-6 in CSC/sh-WNT5B M2 hetero-
spheroids, we also observed reduced phosphorylated
STAT3 (42.4 ± 5.5%) in immunoblots compared to CSC/
M2 hetero-Additional file 1: Figure S7). Lastly, we ex-
plored the possibility of WNT-driven WNT signaling in
CSCs, in response to macrophage WNT5B. We ob-
served through gene expression analysis that several
WNT ligands were significantly over-expressed in CSCs
co-cultured with M2 macrophages, and there was a loss
in WNT ligand expression upon co-culture with sh-
WNT5B M2 macrophages (Fig. 5g). Consequently, there
was also an associated ~ 50% loss of β-catenin protein
expression in CSC/sh-WNT5B M2 hetero-spheroids, in-
dicating a lower paracrine WNT activation in CSCs in
co-culture with macrophages where WNT5B was
knocked down (Fig. 5h).
Overall, we observed that although knockdown of
macrophage WNT5B did not alter macrophage M2
phenotype, macrophage-derived WNT5B proved to be a
driver of WNT-activated WNT signaling and IL-6 secre-
tion, responsible partly for the increased CSC pheno-
types observed in CSC/M2 hetero-spheroids.
CSCs conditioned in M2 hetero-spheroid culture are more
tumorigenic in vivo, and shWNT5B macrophage
conditioning inhibits tumorigenicity
Three tested conditions: CSC (mono-spheroids), CSC (M2;
conditioned in hetero-spheroids) and CSC(sh-WNT5B M2;
conditioned in hetero-spheroids) generated tumors in NSG
mice (Fig. 6a). The rate of tumor initiation and kinetics of
growth was significantly different between all three condi-
tions, with CSC(M2) tumors initiating at the fastest rate of
11.97mm3/day. CSC(shWNT5b M2) tumors were signifi-
cantly slower to initiate at 4.74mm3/day, compared to CSC
tumors at 5.89mm3/day. CSC(M2) tumors reached the
maximum tumor burden window earlier, compared to
CSC and CSC(shWNT5B M2) tumors (Fig. 6a). Histologic
examination of the xenografts reveals that the lesions are
composed of solid sheets of tumor cells with epithelioid
morphology. In the CSC group, dense sheets of polygonal
tumor cells with abundant cytoplasm and conspicuous
nuclei are noted, with little intercellular space (Fig. 6b). In
the CSC(M2) group, sheets of large epithelioid tumor cells
with abundant eosinophilic cytoplasm constitute the en-
tire tumor with little intercellular space and stroma. In the
CSC(shWNT5B M2) group, the tumor cells are much
smaller and loosely arranged in cords and strands. Occa-
sional apoptotic cells are seen with a low mitotic count.
Gene expression levels were assessed in xenografted tu-
mors from the three groups, to understand if macrophage
conditioning was maintained in vivo (Fig. 6c). Our data in-
dicated that an elevated ALDH1A1 expression was
retained significantly in CSC(M2) tumors (**, p < 0.001,
two-way ANOVA), compared to CSC(shWNT5B M2) tu-
mors (ns; not significant). Similarly, elevated Wnt ligands
observed in vitro upon CSC/macrophage co-culture in
hetero-spheroids (Fig. 5g) was re-evaluated in xenografts.
We observed the maintenance of a significant elevation in
Wnt2, Wnt3A, and Wnt6 (*p < 0.05, **p < 0.001, two-way
ANOVA) in CSC(M2) tumors compared to CSC tumors.
CSC(shWNT5B M2) tumors were not significantly differ-
ent in Wnt ligand elevation compared to CSC tumors.
Furthermore, we tested the effect of the human IL-6 in-
hibitor Tocilizumab on CSC and CSC(M2) spheroids (Fig.
6d). CSC spheroids were significantly responsive to Toci-
lizumab treatment, evident from the divergent treatment
curve from the control untreated group (purple curves,
Fig. 6d). CSC(M2) tumors were however significantly re-
sistant to Tocilizumab treatment, indicating the elevated
IL6 conditioning activity, in line with elevated ALDH1A1
gene expression and elevated Wnt ligand expression.
Change in tumor burden with Tocilizumab treatment in
CSC spheroids ranged between 67.7–70.7%, while in
CSC(M2) tumors, the reduction was merely 23.8–24% of
control tumor volumes.
Discussion
Macrophages play an important role in tissue homeostasis,
with tumor-associated macrophages promoting cancer pro-
gression, metastasis, angiogenesis and tumorigenicity.
Tumor-associated macrophages are a major fraction of
cells within the epithelial ovarian cancer ascites microenvir-
onment [23, 24], and are responsible for recurrence and
metastasis of ovarian cancer, including promotion of resist-
ance and the preservation of a more de-differentiated, i.e.
stem-like cancer cell phenotype [7, 25]. Given the enriched
presence of CSCs and the abundant presence of macro-
phages within the malignant ascites [1, 2, 11], we opted to
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use a hetero-spheroid model to bring both these cells in
close association within one 3D structure in vitro. The pri-
mary advantage of this model is that it facilitates cell-cell
interactions in a 3D microenvironment [13–15]. Therefore,
the hanging drop spheroid model is uniquely positioned to
understand how ovarian CSCs and macrophages interact
with each other (simulating their presence within the asci-
tes), and specifically, test our hypotheses: i) CSCs activate
macrophages differently comparing to the bulk ovarian
cancer cells; and ii) the activated macrophages promote
functional CSC phenotypes.
In our experiments, we observed similar levels of dif-
ferentiation and subsequent activation of macrophages
by using the 3D platform, compared to monocytes dif-
ferentiated and activated traditionally in 2D tissue cul-
ture plates by us (Additional file 1: Figure S1) and others
[26–28]. Interestingly, along with clear hallmarks of al-
ternate macrophage activation (IL-10 secretion, CD163
Fig. 5 Macrophage knockdown of Wnt5b suppresses ALDH enrichment, with no change in CD206, and increases chemosensitivity of hetero-
spheroids. a Flow analysis of CD206 indicated no significant differences in CSC/M2 and CSC/Scramble M2 and CSC/shWnt5b M2 hetero-
spheroids, indicating that CSCs were still capable of maintaining a robust immunosuppressive program in hetero-spheroids, regardless of WNT5B.
b ALDH elevation however was significantly (*p < 0.05, one-way ANOVA) lowered compared to CSC/U937 M2 hetero-spheroids, and not
significantly different (ns) compared to CSC mono-spheroids, indicating that knocking down Wnt5b expression in macrophages reduced ALDH
enrichment in hetero-spheroids. c Concomitant with the decrease in ALDH, sensitivity to carboplatin also significantly (**p < 0.001, one-way
ANOVA) improved, responding to treatment similar to CSC mono-spheroids. The red dashed line indicates the sensitivity levels of CSC mono-
spheroids. d CSC/shWnt5b M2 hetero-spheroids were also significantly (***p < 0.0001, t-test) less invasive than CSC/Scramble M2 hetero-
spheroids. e Upon ELISA analysis of secreted IL10 and IL6, we found no changes in IL-10 levels, while we found a stark decrease in secreted pro-
tumoral IL-6 cytokine in CSC/shWnt5b M2 hetero-spheroids. f Exogenous addition of IL-6 (25 ng/ml) to CSC/shWnt5b M2 hetero-spheroids
partially significantly (*p < 0.05, one-way ANOVA) increases ALDH+ enrichment, but does not restore it to levels of original enrichment with CSC/
Scramble M2 or CSC/Ctrl M2 hetero-spheroids. g In order to identify if there was paracrine macrophage Wnt-driven Wnt signaling in CSCs, we
separated the CSCs (using a GFP label) from hetero-spheroids, and probed for gene expression of several Wnt ligands we saw elevated in CSCs
compared to bulk OVCAR3. We observed that with M2 macrophage co-culture, several Wnt ligands were upregulated (Wnt2 significantly
elevated, ***p < 0.001, two-way ANOVA). However, this elevated gene expression of Wnt ligands was lost in CSCs in hetero-spheroid culture with
shWnt5b M2, indicating that Wnt5b was partly responsible for potentiating Wnt signaling within the CSC compartment. h This loss in Wnt ligand
expression also translated to decreased β-catenin expression in CSC/shWnt5b M2 hetero-spheroids compared to CSC/U937M2 hetero-spheroids,
quantified by densitometry of immunoblots (representative blot shown)
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and CD206 gene expression), we also observe an ele-
vated macrophage secretion of IL-6, which is not typic-
ally associated with M2 macrophages, but is observed in
bipolar tumor associated macrophage populations in the
malignant ascites of ovarian cancer [11, 29].
In CSC/macrophage hetero-spheroids, we find that
CD68+ macrophages make up ~ 20% of the population at
day 5, even though they start at 50% initially, likely due to
CSC proliferation taking over the spheroid. Our results
suggest that CSCs have an intrinsically higher immuno-
suppressive program, driving CD206 expression in M0
macrophages to a larger extent than bulk unsorted ovarian
cancer cells, evident also by the increased IL10 gene ex-
pression in CSCs. This observation is in line with results
observed in literature where ovarian cancer cells activate
macrophages to alternative M2-like pro-tumoral phenotype
[9, 30]. Indeed, macrophages exposed to IL-10 are known
to polarize into M2 phenotypes [31, 32] under sustained
IL-10 exposure, and CSCs from ovarian and other cancers
can induce pro-tumoral macrophage phenotypes through
other pathways including NF-kB [33, 34].
Consequently, we determined that hetero-spheroids
with alternatively activated M2-like macrophages in-
creased maintenance of the ALDH+ CSC populations.
This is in line with observations in ovarian, breast and
hepatocellular carcinomas, where tumor-associated mac-
rophages induce stemness and increase CSCs [25, 35,
36]. In our experiments, ALDH+ increase could also be
correlated with increased levels of the cytokine IL-6 in
M2 hetero-spheroids. The involvement of M2-derived
IL-6 is further strengthened by the fall in ALDH+ en-
richment with inhibitors of the IL-6/STAT3 signaling
Fig. 6 Changes in tumorigenicity of hetero-spheroids in vivo in NSG mice. Tumors were generated in NSG mice from CSC mono-spheroids, or
CSCs isolated from hetero-spheroids in CSC/M2 or CSC/shWNT5b M2. a Tumor initiation and growth kinetics are shown for all three groups,
where CSC(M2) tumors (red curve) demonstrates elevated tumorigenicity, with faster tumor initiation and tumor burden development (gray
shaded area indicates the tumor burden window). Similarly, the blue trace indicates the tumor growth in CSC/shWNT5b M2 tumors, which is
significantly (*p < 0.05, two-way ANOVA) lower and slower compared to CSC and CSC(M2) groups at the time points indicated. b Histological
examination demonstrates that all groups establish similar structures of tumors sub-cutaneously, with CSC tumors and CSC (M2) tumors
establishing dense epitheliod cells, with CSC (shWNT5b M2) tumors more loosely arranged. Scale bar = 100 μm. c Gene expression analysis of
xenografted tumors indicated that an elevated ALDH1A1 expression was maintained in CSC(M2) tumors (**p < 0.001, two-way ANOVA). M2-like
macrophage conditioning also helped CSCs retain elevated expression of WNT2, WNT3A and WNT6 (*p < 0.05, **p < 0.001, two-way ANOVA)
compared to CSCs in mono-spheroids. All other genes and conditions were not significantly different (ns) compared to CSCs, specifically CSC/
shWnt5B M2 tumors. d The human IL-6 inhibitor Tocilizumab was used intra-peritoneally on CSC and CSC(M2) tumors, once palpable tumors
were observed (Day 25), indicated by the arrow. Tocilizumab treatment resulted in a significant decrease in tumor volume (**p < 0.001, two-way
ANOVA) compared to control untreated tumors in CSC mono-spheroid tumors (compare purple trace to black trace; ~ 70% reduction in tumor
burden). However, in CSC/M2 tumors, tocilizumab treatment did not significantly alter the growth kinetics of treated vs. untreated tumors (~ 24%
reduction in tumor burden), indicating the detainment of a chemoresistant phenotype upon M2-like macrophage co-culture and conditioning.
Furthermore, the treated CSC Tocilizumab condition also resembles the control CSC (shWNT5B M2) tumors (blue trace in A), indicating that partial
loss or inhibition of IL-6 based CSC enrichment may be at play
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axis (Ruxolitinib, SC144, and Tocilizumab). The increase
in ALDH+ enrichment and the emergence of CD206+
macrophages was also observed in CSC/M0-M2 hetero-
spheroids generated from an additional high-grade serous
cell line, Kuramochi (Additional file 1: Figure S8) and
tumor cells and CSCs from a high-grade serous primary
ovarian carcinoma sample Additional file 1: Figure S9).
The WNT/β-catenin pathway is heavily implicated in
the maintenance of CSCs in ovarian cancer, so much so,
that it is an attractive therapeutic target [37–39]. Hence,
the elevation of several WNT ligands in CSCs compared
to bulk OVCAR3 cancer cells is unsurprising, as we ob-
serve in our results. It is however likely, that some of the
CSC-derived WNT ligands could potentially drive M2-
like alternate macrophage activation, as evidenced in other
pathologies where the involvement of WNT3A, WNT6
and other WNT ligands drive alternative macrophage ac-
tivation [20, 40].
In our experiments, we found that macrophage-
specific inhibition of WNT secretion resulted in a sig-
nificant reduction in ALDH+ enrichment in hetero-
spheroids, implying that WNT signaling was likely in-
volved bi-directionally in CSC/macrophage interactions.
The lone WNT ligand we found significantly upregu-
lated in M2-like macrophages (compared to monocytes
or M0 macrophages) was WNT5B, in line with tran-
scriptomic and gene expression analyses performed on
human M2 macrophages by other groups [41, 42]. Inter-
estingly, macrophage WNT5B knockdown resulted in
the loss of ALDH+ enrichment in the CSC compartment
of hetero-spheroids, with an associated loss of IL-6 se-
cretion. In other pathogenic states, activation of WNT5B
is associated with IL-6 secretion [43, 44], and hence, it is
not surprising that we observe the loss in IL-6 upon
WNT5B knockdown. Exogenous addition of IL-6 par-
tially restores elevated ALDH levels in CSC/sh-WNT5B
M2 hetero-spheroids, indicating that IL-6 is at least partly
responsible for the observed phenotype. Additionally, we
also observed that several WNT ligands were upregulated
in the CSC compartment of hetero-spheroids cultured in
CSC/M2 compared to CSC mono-spheroids, and the up-
regulation dropped in CSCs cultured in CSC/sh-Wnt5b
M2 hetero-spheroids. Tumor stroma-derived WNT
ligands like WNT3 and WNT5B are critical factors that
instigate invasive behavior, and induction of an EMT
phenotype in tumor epithelial cells [45]. In fact, WNT5B
associated exosomes promoted cancer cell migration and
proliferation in a paracrine manner [46].
This points to enhanced Wnt signaling within the
CSC compartment upon co-culture with alternatively
activated M2-like macrophages, likely mediated by se-
creted Wnt (specifically also WNT5B) arising from the
macrophage compartment, in line with several observa-
tions where tumor associated/M2 macrophages increase
Wnt signaling in epithelial cells [22, 47–49].
The tumor-intrinsic WNT-β-catenin signaling is
shown to promote a T-cell exclusion phenotype [18].
Utilizing a robust immune deconvolution algorithm, we
analyzed high-grade serous carcinomas and found a con-
sistent phenotype, suggesting that the tumor-intrinsic
WNT-β-catenin activation may promote immune sup-
pression across cancer types (Additional file 1: Figure
S10). However, the cellular mechanism underpinning
this link remained less characterized. This study employs
a high-fidelity 3D culture model to reveal the reverse
link between the expression levels of WNT5B in alterna-
tively activated macrophages and cancer cells, possibly
leading to T-cell exclusion. However, it is important to
Fig. 7 Ovarian cancer stem cells and macrophages reciprocally interact through the Wnt pathway to promote a pro-tumoral microenvironment.
Our data suggests that in hetero-spheroids, CSCs drive a CD206+ expressing macrophage phenotype, suggestive of pro-tumoral M2 activation
through secretion of the immuno-suppressive cytokine IL-10, and through WNT ligands. We also observe that macrophage-derived WNT ligands,
specifically WNT5B, and to some extent the pro-tumoral cytokine IL-6, drive an enrichment in ALDH+ cells within hetero-spheroids. Knockdown of
macrophage WNT5B expression, or inhibiting downstream activation of IL-6 using Ruxolitinib or sc144, result in a significant loss of ALDH+
populations within hetero-spheroids. Importantly, we find that the Wnt pathway is involved bi-directionally in CSC-macrophage interactions, and
can potentially be targeted to reduce stemness, chemoresistance, invasiveness and immunosuppression in ovarian cancer
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note that the WNT signaling pathway has pleotropic ef-
fects on a broad range of cell types including several
types of immune cells [50, 51]. Recent studies show that
Wnt pathway is also crucial for the development of T-
cells [52]. The Wnt-β-catenin pathway maintains the
multipotency of memory CD8+ T-cells with anti-tumor
properties [53]. Thus, dosing, treatment schedule, and
relatively more specific tumor-targeted delivery ap-
proaches are likely important to unleash the potential of
the immune-priming properties of WNT-β-catenin
inhibitors.
In conclusion, we demonstrate a robust hetero-
spheroid culture system, where ovarian CSCs and acti-
vated macrophages can be brought in close association
in a 3D in vitro microenvironment, simulating their
non-adherent presence within malignant ascites. We
demonstrate the presence of macrophages within spher-
oids and their pro-tumoral activation by CSCs. Recipro-
cally, pro-tumoral activated macrophages also promote a
chemoresistant and invasive phenotype of the CSC com-
partment and its enrichment within hetero-spheroids,
potentially contributing to highly malignant and meta-
static disease (Fig. 7). Lastly, we were able to understand
the reciprocal involvement of the WNT pathway, with
activation of paracrine WNT signaling by macrophages
in ovarian CSCs, with wide-implications for new thera-
peutic targets to specifically eradicate the immuno-
modulation of macrophages by CSCs that contribute to
recurrent disease.
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